Ajanta Pharma’s anti-obesity pivot: 4 reasons why Motilal Oswal sees 17% upside
- Posted on December 31, 2025
- By Financial Express
- 5 Views
Ajanta Pharma’s anti-obesity pivot: 4 reasons why Motilal Oswal sees 17% upside
Ajanta Pharma eyes new growth with anti-obesity pivot; Motilal Oswal sees 17% upside—read why you should consider this stock now.
